Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Noninvasive, microbiome-based diagnosis of inflammatory bowel disease.
Zheng J, Sun Q, Zhang M, Liu C, Su Q, Zhang L, Xu Z, Lu W, Ching J, Tang W, Cheung CP, Hamilton AL, Wilson O'Brien AL, Wei SC, Bernstein CN, Rubin DT, Chang EB, Morrison M, Kamm MA, Chan FKL, Zhang J, Ng SC. Zheng J, et al. Among authors: hamilton al. Nat Med. 2024 Dec;30(12):3555-3567. doi: 10.1038/s41591-024-03280-4. Epub 2024 Oct 4. Nat Med. 2024. PMID: 39367251 Free PMC article.
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB, Dervieux T. Spencer EA, et al. Among authors: hamilton al. Front Immunol. 2024 Jan 23;15:1342477. doi: 10.3389/fimmu.2024.1342477. eCollection 2024. Front Immunol. 2024. PMID: 38476237 Free PMC article.
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB, Dervieux T. Spencer EA, et al. Among authors: hamilton al. Front Immunol. 2024 Feb 27;15:1383704. doi: 10.3389/fimmu.2024.1383704. eCollection 2024. Front Immunol. 2024. PMID: 38476224 Free PMC article.
Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
Wright EK, Chaparro M, Gionchetti P, Hamilton AL, Schulberg J, Gisbert JP, Chiara Valerii M, Rizzello F, De Cruz P, Panetta JC, Everts-van der Wind A, Kamm MA, Dervieux T. Wright EK, et al. Among authors: hamilton al. J Crohns Colitis. 2024 Feb 26;18(2):212-222. doi: 10.1093/ecco-jcc/jjad140. J Crohns Colitis. 2024. PMID: 37594369
Effect of food additives on key bacterial taxa and the mucosa-associated microbiota in Crohn's disease. The ENIGMA study.
Loayza JJJ, Kang S, Schooth L, Teh JJ, de Klerk A, Noon EK, Zhang J, Hu J, Hamilton AL, Wilson-O'Brien A, Trakman GL, Lin W, Ching J, Or L, Sung JJY, Yu J, Ng SC, Kamm MA, Morrison M. Loayza JJJ, et al. Among authors: hamilton al. Gut Microbes. 2023 Jan-Dec;15(1):2172670. doi: 10.1080/19490976.2023.2172670. Gut Microbes. 2023. PMID: 36852457 Free PMC article.
86 results